The EMA has recommended label expansions for Inaqovi, Opdivo, and Venclyxto, broadening treatment options in AML, Hodgkin lymphoma, and CLL.

The EMA has recommended updating Comirnaty 10 mg formulations, including JN.1, KP.2, and LP.8.1 versions, to allow COVID-19 vaccination in individuals aged 6 months or older.

This was a cohort of individuals with diabetes who were recently diagnosed and treated at regional care centers throughout ...

European regulators have recommended expanding use of the IL-23 inhibitor Skyrizi to treat moderate-to-severe plaque psoriasis in children aged 6 years or older who require systemic therapy.

Intraoperative reirradiation in combination with a second breast-conserving surgery is safe and well tolerated in patients ...

Patients with HIV infection who receive a liver transplant may face a similar risk of developing new cancers as those without ...

Patients with chronic kidney disease are often taken off RAS inhibitors after declines in kidney function, but the risks may ...

Corticosteroids are associated with reduced cough severity and improved cough-related quality of life in patients with ...

Researchers conducted a retrospective cross-sectional analysis of patients diagnosed with de novo metastatic breast cancer to evaluate presentation and treatment differences across three main subtypes ...

Individuals who only use heated tobacco products do not have a lower risk for type 2 diabetes than those who only smoke ...

A small Italian study suggests a way to safely reduce gastrectomy rates in microsatellite instability-high disease.

The EMA has backed broader pediatric use of Agamree and Crysvita, lowering age thresholds for rare genetic diseases affecting muscle and bone development.